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Background: Left ventricular ejection function (LVEF) recovers in the majority of
patients with aortic stenosis (AS) who undergo aortic valve replacement. However the
outcomes of patients with low EF who undergo transcatheter aortic valve replacement
(TAVR) are not well defined.
Methods: Retrospective analysis of AS patients with normal versus mildly or severely
impaired left ventricular function who underwent TAVR was done. Patients were divided
according to baseline LVEF as normal (LVEF  0.50), mild-moderate (0.40  EF 
0.50) and severe (LVEF0.40) dysfunction.
Results: A total of 242 patients were included in the present analysis. 163 patients (67%)
had normal LVEF, 43 had mild-moderate (18%) and 36 (15%) had severe LV
dysfunction. Baseline demographics were generally comparable apart from higher rates of
women and STS score among patients with LV dysfunction (Table). There was no
difference in access approach with 72% of the patient having transfemoral access. No
significant difference in the in hospital and long term outcome were found (Table).
Conclusions: Patients with severe AS and impaired LV function who undergo TAVR
may gain similar benefit from the procedure as patients with normal LV function.
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Background: Edwards Sapien transcatheter valve is FDA approved for commercial use
in non-operable patients with severe symptomatic aortic stenosis (AS) via the transfemoral
approach.
Objective: To assess the clinical profile and in-hospital complications in patients treated
with commercial valve compared to PARTNER cohort B.
Methods: Study included all consecutive patients treated with commercial Sapien valve
at our institution. Baseline characteristics, clinical presentation and in-hospital complica-
tions were analyzed. Among all trasfemoral cases 37 commercial valve patients were
compared to 54 patients in cohort B.
Results: All clinical variables are similar between the groups including STS score (9.44
vs. 10.75, p0.24) except commercial patients had more insulin dependent diabetes
mellitus and dialysis dependent renal failure. In majority of the patients in the commercial
arm the procedure was done with conscious sedation (81% vs. 56%, p0.02). The use of
planned surgical cut down for vascular access is also rare (4% vs. 85%, P0.001) in
commercial group. 100% procedural success in both the groups with valve deployment.
There is trend for lower vascular and bleeding complications with less blood transfusion
rates (27% vs. 59%, p0.007) in the commercial patients. The in-hospital mortality and
stroke rates are similar between the groups.
Conclusions: The initial commercial use of the Edwards Sapien valve for inoperable
patients reported to have similar success rates in valve deployment, in-hospital mortality
and stroke rate when compared to PARTNER cohort B patients. The refinement in the
procedure with more conscious sedation, experience of the operators and careful vascular
planning with more percutaneous access in the commercial group lead to the trends for
lower vascular complications and the requirement of blood transfusions.
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